Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab
CARDIOLOGY IN THE YOUNG, cilt.29, sa.4, ss.549-551, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 4
- Basım Tarihi: 2019
- Doi Numarası: 10.1017/s1047951119000672
- Dergi Adı: CARDIOLOGY IN THE YOUNG
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.549-551
- Anahtar Kelimeler: Idiopathic recurrent pericarditis, treatment, anti-IL 1 agents, RECEPTOR ANTAGONIST ANAKINRA
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Conventional algorithm for treatment of pericarditis and prevention of recurrences consists of non-steroid anti-inflammatory drugs and/or colchicine, followed by corticosteroids in resistant patients. Anakinra has emerged as a promising and safe treatment modality for steroid-dependent idiopathic recurrent pericarditis. However, the efficacy and safety of canakinumab, another anti-interleukin-1 agent, has not been assessed up to date. Herein, we present development of an anaphylactic reaction due to anakinra and a successful subsequent treatment with canakinumab for the first time in the literature.